DNA

New study characterizes protein’s role in regulating DNA replication in human cancer cells

Jul 20, 2018

Center for Cancer Research investigators have found that the RepID protein recruits the CRL4 protein complex to chromatin early in the cell cycle, playing a critical role in regulating DNA replication. The findings suggest possible therapeutic targets to tighten the reigns on DNA replication. Read more...

Alveolar rhabdomyosarcoma

Blocking MEK signaling pathway could inhibit rhabdomyosarcoma growth

Jul 18, 2018

New CCR research shows that a form of a cancer that occurs mainly in children, embryonal rhabdomyosarcoma, which is driven by mutations to the RAS gene, may be susceptible to inhibition by drugs that target a pathway in which MEK protein signaling, triggered by RAS, plays an important role. This new mechanistic understanding of a complex biological process led investigators to test a drug, trametinib, in mice implanted with the cancer. Their findings show that trametinib might be a good agent to test in clinical trials for this disease. Read more...

Multiple myeloma

CAR T-cell therapy proves effective against multiple myeloma

Jun 27, 2018

A first-in-human clinical trial of multiple myeloma-targeted CAR T cells produced remissions in patients with advanced disease who had received numerous prior treatments. Read more...

DLBCL

Protein complex could be key to drug responsiveness in lymphoma patients

Jun 26, 2018

Continuing a decades-long refinement in understanding how and why a drug is more effective in some patients with lymphoma than others has led to the discovery of a complex of proteins that affects drug responsiveness. Read more...

Cryo-EM

New cryo-EM images provide blueprint for drug development

Jun 18, 2018

In a recent collaborative study published in Nature, CCR researchers have visualized the interaction between two critical components of the body’s cellular communication network using cryo-electron microscopy (cryo-EM). The near-atomic resolution images provide a blueprint that could lead to more effective medications for cancer and other conditions. According to Sriram Subramaniam, Ph.D., Senior Investigator in the Laboratory of Cell Biology and a senior author of the study, “The use of cryo-EM technology to obtain structural information on important pharmaceutical targets such as GPCRs in various states demonstrates that we are now in a position to apply these methods for drug discovery applications.” Read more...

New cryo-EM images provide blueprint for drug development
hairy cell leukemia

Clinical trial suggests moxetumomab pasudotox may be an effective treatment for hairy cell leukemia

Jun 15, 2018

Findings from a phase III international clinical trial, led by Robert Kreitman, M.D., Senior Investigator in the Laboratory of Molecular Biology (LMB), show moxetumomab pasudotox (Moxe) may be an effective treatment option for patients with relapsed or refractory hairy cell leukemia (HCL). Initially developed by an LMB team led by Ira Pastan, M.D., Moxe is a toxin-based drug that can eliminate tiny deposits of cancer cells hiding in bone marrow – referred to as minimal residual disease. These deposits often avoid being killed by standard chemotherapy and are thought to be the cause of relapsed HCL. According to Dr. Kreitman, Moxe offers an option for HCL patients to avoid additional chemotherapy and may potentially improve long-term outcomes.  Read more...

Clinical trial suggests moxetumomab pasudotox may be an effective treatment for hairy cell leukemia
Travis at The Children's Inn

Pediatric clinical trial supports use of selumetinib for children with neurofibromatosis type 1

Jun 15, 2018

Preliminary results from a phase II clinical trial at the Center for Cancer Research support the use of the investigational drug selumetinib for shrinking tumors in children and young adults with neurofibromatosis type 1 (NF1). NF1 is a genetic syndrome that often causes tumors, called plexiform neurofibromas, to develop in nerve cells on or under the skin. Although most of these tumors are not cancerous, patients commonly experience pain, reduced mobility and difficulty breathing. Results from the study, led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch, not only confirm findings from a smaller 2016 study demonstrating the drug’s ability to shrink large tumors, but also suggest the drug may improve symptoms. Read more...

Pediatric clinical trial supports use of selumetinib for children with neurofibromatosis type 1
Cell division in breast cancer

Committing to cell division may be clue to cancer cell growth

Jun 6, 2018

In a new study in Nature, CCR researchers describe, for the first time, how a cell commits to dividing during the cell cycle. Since cancer cells divide when they should not, targeting this pathway might stop their inappropriate growth. Read more...

Tumor cell

Antibody-linked drug shrinks various types of tumors in preclinical study

Jun 5, 2018

A preclinical study by Center for Cancer Research investigators and colleagues shows that a drug guided by an attached target-seeking antibody can recognize cells infiltrating tumors, the tumor stroma, and cause various types of tumors to shrink, and in many cases, disappear. Their findings suggest that when stromal cells take up the ADC, they cleave the drug from the antibody and release it to kill neighboring tumor cells. Read more...

gut bacteria

New study finds gut microbiome can control antitumor immune function in liver

May 24, 2018

Scientists led by Tim Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study published May 24, 2018, in Science and showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them. Read more...

New study finds gut microbiome can control antitumor immune function in liver

Pages